Table 4.
Performance of Immunological Failure Criteria to Predict Various Levels of Virological Failure Among Patients Receiving First-Line Antiretroviral Therapy
| CF | IO | VO | CU | SENS | SPEC | Efficiency | PPV | NPV | |
|---|---|---|---|---|---|---|---|---|---|
| VL>5000 copies/ml | |||||||||
| 6 months | 87 | 7 | 13 | 2 | 13.3 | 92.5 | 81.7 | 22.2 | 87 |
| 12 months | 61 | 9 | 16 | 2 | 11.1 | 87.1 | 71.6 | 18.2 | 79.2 |
| VL>500 copies/ml | |||||||||
| 6 months | 78 | 16 | 13 | 2 | 13.3 | 83 | 73.4 | 11.1 | 85.7 |
| 12 months | 55 | 15 | 13 | 5 | 27.8 | 78.6 | 68.9 | 25 | 80.9 |
| VL>50 copies/ml | |||||||||
| 6 months | 28 | 66 | 9 | 6 | 40 | 29.8 | 31.2 | 8.3 | 75.7 |
| 12 months | 47 | 23 | 12 | 6 | 33.3 | 67.1 | 60.2 | 20.7 | 79.7 |
CF, concordant favorable responders; IO, immunological only responders; VO, virological only responders; CU, concordant unfavorable responders; VL, viral load; SENS, sensitivity; SPEC, specificity; PPV, positive predictive value; NPV, negative predictive value.